Advanced Solid Tumor Clinical Trials

122 studies are recruiting for advanced solid tumor in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 5

1. AMT-116 in Patients With Advanced Solid Tumors

   This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mary Crowley Cancer Research Centers, Dallas, Texas

   Locations

   10 in total

   Run by

   Multitude Therapeutics Inc.

   See if you can join NCT05725291 on ClinicalTrials.gov

2. A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

   This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab in subjects with advanced solid tumors for whom no standard therapy is…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cleveland Clinic, Cleveland, Ohio

   Locations

   5 in total

   Run by

   1ST Biotherapeutics, Inc.

   See if you can join NCT05761223 on ClinicalTrials.gov

3. Study of SGR-3515 In Participants With Advanced Solid Tumors.

   The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University, Yale Cancer Center, New Haven, Connecticut

   Locations

   14 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT06463340 on ClinicalTrials.gov

4. A Beta-only IL-2 ImmunoTherapY Study

   This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sharp Memorial Hospital, San Diego, California

   Locations

   27 in total

   Run by

   Medicenna Therapeutics, Inc.

   See if you can join NCT05086692 on ClinicalTrials.gov

5. A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

   This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalati…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cancer Hospital of Shandong First Medical University, Jinan, Shandong

   Locations

   4 in total

   Run by

   Latticon Antibody Therapeutics, Inc

   See if you can join NCT06277219 on ClinicalTrials.gov

6. A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

   This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and max…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Run by

   Fox Chase Cancer Center

   See if you can join NCT04827810 on ClinicalTrials.gov

7. A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

   This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid tumors During dose escalation, the recommended dose(s) of SOT201 given ev…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   7 in total

   Run by

   SOTIO Biotech AG

   See if you can join NCT06163391 on ClinicalTrials.gov

8. A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

   This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical …

   Stage

   Phase 2

   Ages

   0 to 25

   Site

   UCSF Benioff Children's Hospital, San Francisco, California

   Locations

   35 in total

   Run by

   Day One Biopharmaceuticals, Inc.

   See if you can join NCT04775485 on ClinicalTrials.gov

9. Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

   This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Beijing Cancer Hospital, Beijing, Beijing Municipality

   Locations

   8 in total

   Run by

   Impact Therapeutics, Inc.

   See if you can join NCT05269316 on ClinicalTrials.gov

10. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

    TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The s…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    D&H Cancer Research Center Llc, Margate, Florida

    Locations

    4 in total

    Run by

    Shanghai Allink Biotherapeutics Co., Ltd.

    See if you can join NCT06707610 on ClinicalTrials.gov

11. A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

    This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBC…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

    Locations

    5 in total

    Run by

    Ranok Therapeutics (Hangzhou) Co., Ltd.

    See if you can join NCT05487170 on ClinicalTrials.gov

12. A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

    This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Phoenix, Phoenix, Arizona

    Locations

    10 in total

    Run by

    TORL Biotherapeutics, LLC

    See if you can join NCT06005740 on ClinicalTrials.gov

13. This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

    This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary antitumor activity, and the PD effect of ABL503 in subjects with any progre…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    8 in total

    Run by

    ABL Bio, Inc.

    See if you can join NCT04762641 on ClinicalTrials.gov

14. A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

    This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination with fulvestrant in subjects with advanced solid tumors. The study wil…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists, Lake Mary, Florida

    Locations

    6 in total

    Run by

    Edgewood Oncology Inc.

    See if you can join NCT04872166 on ClinicalTrials.gov

15. A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

    This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subje…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Austin, Austin, Texas

    Locations

    4 in total

    Run by

    OncoResponse, Inc.

    See if you can join NCT06090266 on ClinicalTrials.gov

16. A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

    It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Horizon Oncology, Lafayette, Indiana

    Locations

    4 in total

    Run by

    Shanghai Huaota Biopharmaceutical Co., Ltd.

    See if you can join NCT05417321 on ClinicalTrials.gov

17. Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

    Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the un…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Irvine, Irvine, California

    Locations

    4 in total

    Run by

    CJ Bioscience, Inc.

    See if you can join NCT05877430 on ClinicalTrials.gov

18. A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic in Arizona, Scottsdale, Arizona

    Locations

    11 in total

    Run by

    GI Innovation, Inc.

    See if you can join NCT05824975 on ClinicalTrials.gov

19. EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

    This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    Eisbach Bio GmbH

    See if you can join NCT06525298 on ClinicalTrials.gov

20. Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

    This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid tumors. The main purpose of Phase 1 is to determined the recommended Phase 2 dose (RP2D) of TU2218 …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    3 in total

    Run by

    TiumBio Co., Ltd.

    See if you can join NCT05204862 on ClinicalTrials.gov

21. AIMS Cancer Outcomes Study

    The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect …

    Stage

    Not phased

    Ages

    Any age

    Site

    AIMS Institute, Seattle, Washington

    Run by

    Advanced Integrative Medical Science Institute

    See if you can join NCT04495790 on ClinicalTrials.gov

22. A Study in Patients With Advanced Cancers

    A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology Austin, Austin, Texas

    Locations

    3 in total

    Run by

    BiOneCure Therapeutics Inc.

    See if you can join NCT05320588 on ClinicalTrials.gov